Products


arrowPrescription Medicines

The following list includes the company's prescription products in the United States. To view the Prescribing Information, Patient Information, or Material Safety Data Sheets (MSDS), you will need the Adobe Acrobat Reader plug-in installed in your browser. Prescribing Information is for United States Residents Only.

 

Hydromorphone Hydrochloride Oral Solution, USP Hydromorphone Hydrochloride Oral Solution, USP
Authorized Generic of Dilaudid®(hydromorphone hydrochloride) Oral Liquid

IMPORTANT SAFETY INFORMATION

WARNING: HYDROMORPHONE HYDROCHLORIDE ORAL SOLUTION, USP CONTAINS HYDROMORPHONE, WHICH IS A POTENT SCHEDULE II CONTROLLED OPIOID AGONIST. SCHEDULE II OPIOID AGONISTS,
INCLUDING MORPHINE, OXYMORPHONE, OXYCODONE, FENTANYL, AND METHADONE, HAVE THE HIGHEST POTENTIAL FOR ABUSE AND RISK OF PRODUCING RESPIRATORY DEPRESSION. ALCOHOL, OTHER OPIOIDS AND CENTRAL NERVOUS SYSTEM DEPRESSANTS (SEDATIVEHYPNOTICS) POTENTIATE THE RESPIRATORY DEPRESSANT EFFECTS OF HYDROMORPHONE, INCREASING THE RISK OF RESPIRATORY DEPRESSION THAT MIGHT RESULT IN DEATH.


 

Theophylline (Androus) Extended-Release Tablets Theophylline (Androus) Extended-Release Tablets

 

Morphone Sulfate Morphine Sulfate Extended-Release Tablets


IMPORTANT SAFETY INFORMATION

WARNING:

Morphine Sulfate Extended-Release Tablets contain morphine sulfate, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics.

Morphine can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing Morphine Sulfate Extended-Release Tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

Morphine Sulfate Extended-Release Tablets are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Morphine Sulfate Extended-Release Tablets are NOT intended for use as a prn analgesic.
Morphine Sulfate Extended-Release 100 and 200 mg Tablets ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. These tablet strengths may cause fatal respiratory depression when administered to patients not previously exposed to opioids.

MORPHINE SULFATE EXTENDED-RELEASE TABLETS ARE TO BE SWALLOWED WHOLE AND ARE NOT TO BE BROKEN, CHEWED, DISSOLVED, OR CRUSHED. TAKING BROKEN, CHEWED, DISSOLVED, OR CRUSHED MORPHINE SULFATE EXTENDED-RELEASE TABLETS LEADS TO RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF MORPHIN


 


Hydromorphone Hydromorphone Hydrochloride Tablets, USP
Authorized Generic of Dilaudid® (hydromorphone hydrochloride)

IMPORTANT SAFETY INFORMATION

WARNING: HYDROMORPHONE HYDROCHLORIDE TABLETS, USP CONTAIN HYDROMORPHONE, WHICH IS A POTENT SCHEDULE II CONTROLLED OPIOID AGONIST. SCHEDULE II OPIOID AGONISTS,
INCLUDING MORPHINE, OXYMORPHONE, OXYCODONE, FENTANYL, AND METHADONE, HAVE THE HIGHEST POTENTIAL FOR ABUSE AND RISK OF PRODUCING RESPIRATORY DEPRESSION. ALCOHOL, OTHER OPIOIDS AND CENTRAL NERVOUS SYSTEM DEPRESSANTS (SEDATIVEHYPNOTICS) POTENTIATE THE RESPIRATORY DEPRESSANT EFFECTS OF HYDROMORPHONE, INCREASING THE RISK OF RESPIRATORY DEPRESSION THAT MIGHT RESULT IN DEATH.


 

arrowAuthorized Distributors

Click here for a list of authorized distributors

News Release

Coventry,
R.I., October 1, 2012

News ReleaseRhodes Pharmaceuticals L.P. Announces the Launch of Hydromorphone Hydrochloride Oral Solution, USP ...

read more